Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

Zakiya Rice
Melinda Gooderham
Mark G. Lebwohl
Eric L. Simpson
Mark Boguniewicz
Andreas Wollenberg
Irina Lazariciu
Gary L. Chan
Justine Alderfer
Melissa Watkins

Keywords

Abrocitinib, JAK1 inhibitor, Moderate-to-Severe Atopic Dermatitis, Short-Term Efficacy, Disease Severity

References

1. Simpson et al. J Am Acad Dermatol. 2016;74:491-498.

2. Simpson et al. JAMA Dermatol. 2018;154:903-912.

3. Cibinqo (abrocitinib). Prescribing information. Pfizer Ltd.; September 2021.

4. Cibinqo (abrocitinib). Summary of Product Characteristics. Pfizer Europe; October 2022.

5. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; January 2022.

6. Simpson EL et al. Lancet. 2020;396:255-266.

7. Silverberg JI et al. JAMA Dermatol. 2020;156:863-873.

8. Bieber T et al. N Engl J Med. 2021;384:1101-1112.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 > >>